Document Detail

Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis.
MedLine Citation:
PMID:  14643908     Owner:  NLM     Status:  MEDLINE    
Tacrolimus hydrate (FK506) reduces myasthenic symptoms due to its immunosuppressive properties. We studied the therapeutic effects of FK506 and noted improvement in 7 of 13 myasthenic patients on the clinical muscle test (myasthenia gravis, MG score). Two other patients with relapsing ocular symptoms improved. We also examined patient sensitivity to FK506, but could not predict such sensitivity before FK506 treatment in the present study.
Nobuo Wakata; Toyokazu Saito; Sachiko Tanaka; Toshihiko Hirano; Kitaro Oka
Related Documents :
25298618 - The antioxidant profiles, lysosomal and membrane enzymes activity in patients with acut...
798148 - Effect of trimethylcolchicinic acid methyl ether d-tartrate (tmca) on hodgkin's and non...
15623708 - Etanercept treatment in corticosteroid-dependent myasthenia gravis.
22558258 - Abnormalities of white matter microstructure in unmedicated obsessive-compulsive disord...
9189778 - Defaecography in patients with irritable bowel syndrome and healthy volunteers.
6798888 - Prevalence of slow heart rates in chronic chagas' disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical neurology and neurosurgery     Volume:  106     ISSN:  0303-8467     ISO Abbreviation:  Clin Neurol Neurosurg     Publication Date:  2003 Dec 
Date Detail:
Created Date:  2003-12-03     Completed Date:  2004-03-17     Revised Date:  2009-10-14    
Medline Journal Info:
Nlm Unique ID:  7502039     Medline TA:  Clin Neurol Neurosurg     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  5-8     Citation Subset:  IM    
Fourth Department of Internal Medicine, Toho University School of Medicine, 2-17-6 Oohashi, Meguro-ku, Tokyo 153-8515, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Combined Modality Therapy
Immunosuppressive Agents / adverse effects,  therapeutic use*
Middle Aged
Myasthenia Gravis / diagnosis,  drug therapy*,  immunology
Neurologic Examination / drug effects
Patient Selection*
Prednisolone / therapeutic use
Tacrolimus / adverse effects,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Immunosuppressive Agents; 109581-93-3/Tacrolimus; 50-24-8/Prednisolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Severe myopathy and psychosis in a patient with Cushing's disease macroadenoma.
Next Document:  Postoperative communicating hydrocephalus in patients with supratentorial malignant glioma.